Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Cross Cancer Institute, Edmonton, AB, Canada

Survival: 17.4 months
Toxicity Grade: 2
Treatments: Biologic therapy
Drugs: Cytoxan
Country: Canada
City/State/Province: Edmonton, AB
Hospital: Cross Cancer Institute
Journal: Link
Date: 9/2005

Patients: This Phase II study involved 171 patients with advanced non-small-cell lung cancer who were randomly assigned into two groups. Group A had 88 patients (52 men, 36 women) with a median age of 59.5 years. All patients had either stable disease or a response to prior chemotherapy.

Treatment: The treatment consisted of the use of a biological therapeutic agent. BLP25 is a vaccine that targets the MUC1 protein which is overexpressed in NSCLC tumor cells. Only patients in group A were given BLP25. Patients in this group were also administered chemotherapy (a single dose of cyclophosphamide).

Toxicity: Serious adverse events were reported in 23 (26.1%) of 88 patient in the L-BLP25 arm (Group A). However, these side-effects were not graded.

Results: For Group A, the median overall survival was 17.4 months. For Group B, the median overall survival was 13 months. However, the difference in survival between the groups was not statistically significant. The authors concluded, "The results reported here are promising and suggest that this minimally toxic vaccine might be valuable as maintenance therapy."

Support: Biomira and Merck supported this study, and several authors disclosed relationships with Biomira. Biomira develops and manufactures BLP25.

Correspondence: Charles Butts, MD

E-mail to a Friend Email Physician More Information